Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Glioma progression in diabesity.

Alarcón S, Niechi I, Toledo F, Sobrevia L, Quezada C.

Mol Aspects Med. 2019 Apr;66:62-70. doi: 10.1016/j.mam.2019.02.002. Epub 2019 Mar 4. Review.

PMID:
30822432
2.

Involvement of A2B adenosine receptors as anti-inflammatory in gestational diabesity.

Cabalín C, Villalobos-Labra R, Toledo F, Sobrevia L.

Mol Aspects Med. 2019 Apr;66:31-39. doi: 10.1016/j.mam.2019.01.001. Epub 2019 Jan 24. Review.

PMID:
30664911
3.

Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity.

Villalobos-Labra R, Subiabre M, Toledo F, Pardo F, Sobrevia L.

Mol Aspects Med. 2019 Apr;66:49-61. doi: 10.1016/j.mam.2018.11.001. Epub 2018 Nov 27. Review.

PMID:
30472165
4.

Study design and recruitment for a prospective controlled study of diabesity: Taiwan Diabesity Study.

Lee WJ, Chang YC, Almalki O, Chao SH, Lu CH, Chen CC, Huang YY, Lee YC, Hsu CC.

Asian J Surg. 2019 Jan;42(1):244-250. doi: 10.1016/j.asjsur.2018.02.007. Epub 2018 Apr 6.

5.

Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options.

Potenza MA, Nacci C, De Salvia MA, Sgarra L, Collino M, Montagnani M.

Pharmacol Res. 2017 Jun;120:226-241. doi: 10.1016/j.phrs.2017.04.009. Epub 2017 Apr 10. Review.

6.

Diabesity: an inflammatory metabolic condition.

Schmidt MI, Duncan BB.

Clin Chem Lab Med. 2003 Sep;41(9):1120-30. Review.

PMID:
14598860
7.

Molecular links between Obesity and Diabetes: “Diabesity”.

Chadt A, Scherneck S, Joost HG, Al-Hasani H.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2018 Jan 23.

8.

Altered foetoplacental vascular endothelial signalling to insulin in diabesity.

Pardo F, Subiabre M, Fuentes G, Toledo F, Silva L, Villalobos-Labra R, Sobrevia L.

Mol Aspects Med. 2019 Apr;66:40-48. doi: 10.1016/j.mam.2019.02.003. Epub 2019 Mar 8. Review.

PMID:
30849412
9.

Impaired signalling pathways mediated by extracellular vesicles in diabesity.

Sáez T, Toledo F, Sobrevia L.

Mol Aspects Med. 2019 Apr;66:13-20. doi: 10.1016/j.mam.2018.12.001. Epub 2019 Jan 14. Review.

PMID:
30610887
10.

Diabesity: an overview of a rising epidemic.

Farag YM, Gaballa MR.

Nephrol Dial Transplant. 2011 Jan;26(1):28-35. doi: 10.1093/ndt/gfq576. Epub 2010 Nov 2. Review.

PMID:
21045078
11.

Non-pharmacological Treatment Options in the Management of Diabetes Mellitus.

Raveendran AV, Chacko EC, Pappachan JM.

Eur Endocrinol. 2018 Sep;14(2):31-39. doi: 10.17925/EE.2018.14.2.31. Epub 2018 Sep 10. Review.

13.
14.

Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity.

Vasseur F, Helbecque N, Lobbens S, Vasseur-Delannoy V, Dina C, Clément K, Boutin P, Kadowaki T, Scherer PE, Froguel P.

Diabetologia. 2005 May;48(5):892-9. Epub 2005 Apr 14.

PMID:
15830179
15.

Medical Management of Diabesity: Do We Have Realistic Targets?

Pappachan JM, Viswanath AK.

Curr Diab Rep. 2017 Jan;17(1):4. doi: 10.1007/s11892-017-0828-9. Review.

PMID:
28101792
16.

Extracellular vesicles in obesity and diabetes mellitus.

Pardo F, Villalobos-Labra R, Sobrevia B, Toledo F, Sobrevia L.

Mol Aspects Med. 2018 Apr;60:81-91. doi: 10.1016/j.mam.2017.11.010. Epub 2017 Nov 26. Review.

PMID:
29175307
17.

Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way.

Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D, Woodward E, Toplak H.

Obes Facts. 2017;10(5):483-492. doi: 10.1159/000480525. Epub 2017 Oct 12. Review.

18.

Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'?

Astrup A, Finer N.

Obes Rev. 2000 Oct;1(2):57-9. Review.

PMID:
12119987
19.

Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.

Deol H, Lekkakou L, Viswanath AK, Pappachan JM.

Endocrine. 2017 Jan;55(1):173-178. doi: 10.1007/s12020-016-1125-0. Epub 2016 Sep 30.

PMID:
27696231
20.

Treatment of 'Diabesity': Beyond Pharmacotherapy.

Singh H, Venkatesan V.

Curr Drug Targets. 2018;19(14):1672-1682. doi: 10.2174/1389450119666180621093833.

PMID:
29929463

Supplemental Content

Support Center